16 March 2023
EMA/CHMP/125064/2023

Public statement

NeuroBloc (botulinum toxin type B)

Withdrawal of the marketing authorisation in the European Union

On 9 December 2022, the European Commission withdrew the marketing authorisation for NeuroBloc (botulinum toxin type B) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sloan Pharma S.a.r.l, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

NeuroBloc was granted marketing authorisation in the EU on 22 January 2001 for the treatment of cervical dystonia in adults.

Therapeutic alternatives are available throughout the European Union. Patients taking Neurobloc or participating in a clinical trial are advised to consult their physician.

The European Public Assessment Report (EPAR) for NeuroBloc (SRD) will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union